Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma to Present and Exhibit at Upcoming Investment Conferences in Scottsdale, Arizona, and Orlando, Florida
January 14, 2010

Nutra Pharma has announced that it will be presenting and exhibiting at the upcoming Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference in Scottsdale, Arizona, and at The World MoneyShow in Orlando, Florida.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference in Scottsdale, Arizona, and at The World MoneyShow in Orlando, Florida.

“This is an exciting time for Nutra Pharma as we continue to rollout our first drug products and begin generating our first significant revenues in the history of the Company,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “These conferences provide excellent opportunities to expand our presence within the investment community and share our unique and exciting growth story,” he concluded.

The Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference, which is scheduled for February 1st to February 3rd 2010, will be hosted at the Four Seasons Resort in Scottsdale Arizona. The World MoneyShow is scheduled for February 3rd to February 6th 2010 and will be held at the Gaylord Palms Hotel and Convention Center in Orlando, Florida.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Exhibiting at the upcoming shows in Scottsdale, Arizona, and Orlando, Florida, should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
May 23, 2017
Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures


March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics